This year’s Walk to “Knockout” Parkinson’s Disease will feature a picnic in the park. Beginning at 11 a.m., along with the raffle drawing, enjoy a freshly-cooked Vienna all beef hotdog, chips, and a can of pop for only $3 a meal.

Join us on Saturday, September 8 for this fun family event along the Riverwalk in Naperville, IL. For details, go to www.apdamidwest.org

Event Schedule

8:30 a.m. Check-in

Turn in pledge sheets and donations. 

Make suggested minimum donation of $25 per person and receive one t-shirt. 

Sign waiver for walking.

Enjoy coffee and snacks.   
9:30 a.m. Welcome

Maxine Dust, APDA Midwest Chapter Board President: Opening Remarks

Dr. Michael Rezak: Update on PD research 

10:00 a.m. Walk begins

11:00 a.m. Raffle drawing

Fresh cooked hot dog lunch for sale for $3 including chips and can of pop.

You should have received your pledge sheet with your newsletter. to collect and record pledges and turn it all in at check-in. If you are unable to attend the Walk, make donations on line at www.apdamidwest.org

For more information, call the Midwest Chapter Office at 630-933-4392.

Solanezumab Phase 3 Clinical Trial Results Bring New and Encouraging Information

http://www.businessweek.com/ap/2012-08-24/lilly-alzheimers-drug-trial-yields-promising-sign

http://www.alz.org/

Eli Lilly and Company announced today that two Phase 3 studies of an experimental drug therapy called solanezumab in mild to moderate Alzheimer’s disease did not meet their primary endpoints.

However, there is new and encouraging information in the trial results. According to the company, in a secondary pooled analysis of both studies, the drug at the tested dose showed a statistically significant slowing of cognitive decline in people with mild to moderate Alzheimer’s disease; the results were driven by people with mild Alzheimer’s. If this finding can be duplicated, it suggests that an Alzheimer’s therapy targeting beta amyloid can have a beneficial effect on cognitive abilities in people with mild to moderate Alzheimer’s. That would be a major step forward in the fight against Alzheimer’s disease.

Another hopeful sign is that, according to the company, an open label extension study of this drug will continue. This means that people who were in the Phase 3 trials will have an opportunity to continue taking the drug. This will give us further insight into the effects of this drug over a longer period of time, and also into the value of amyloid-based therapies for people with Alzheimer’s.

The company has only reported “topline” results at this time. More details will be available at the American Neurological Association annual meeting in early October. The company also says that “next steps for solanezumab have not yet been decided and will be determined after discussions with regulators.” The Alzheimer’s Association looks forward to seeing the full data from these studies, and also hearing about the company’s discussions with the FDA about next steps for this drug.

You only have 48 hours left to vote for the Alzheimer’s Association^®! Vote today, and every day, until August 26 in the Subaru “Share the Love” event. It only takes a few mouse clicks–and YOU could be the difference in helping us continue the fight for those living each day with Alzheimer’s disease.

Vote now:   https://www.facebook.com/subaruofamerica/app_345388515542172

Subaru has chosen the Alzheimer’s Association as one of the six charities to compete for a spot in their annual “Share the Love” event. From November 21 through January 2, for every Subaru vehicle, leased or sold, Subaru will make a charitable donation in the amount of $250 to the buyer’s choice of the five participating charities. We could ultimately join 4 other outstanding charities to receive a portion of $5 million dollars.

Only the top two charities get to participate, so we need you. Help the Alzheimer’s Association “Share the Love” by voting right now and each day until August 26. There are only 2 days left, so hurry-and tell a friend!

People often react well when being tested for Alzheimer’s

Some doctors and counselors have discouraged people from undergoing genetic tests that may indicate a probability of developing Alzheimer’s disease. But a series of studies has found that people often manage fine when told their test results, even if they learn they have a higher risk.
Read the article >>

http://www.npr.org/blogs/health/2012/08/16/158919471/grappling-with-the-uncertainty-of-alzheimers-testing?ec=shots&ps=indexstory

Wandering can put person with dementia’s safety in jeopardy

Sixty percent of people with dementia will wander from home. Up to half of the people who wander will suffer serious injury or death if not found within 24 hours. MedicAlert® + Alzheimer’s Association Safe Return® provides 24-hour assistance, no matter when or where the person is reported missing.
Learn more about MedicAlert + Safe Return >>

http://www.alz.org/care/dementia-medic-alert-safe-return.asp?WT.mc_id=enews2012_08_22